StreetAlpha.app
Home › Stocks › VRDN

Viridian Therapeutics, Inc. (VRDN)

Healthcare
$29.96
▼ −4.71%
LAST CLOSE · NOV 20

Viridian Therapeutics is a biopharmaceutical company developing medicines for serious and rare diseases, with a focus on thyroid eye disease. It last closed at $29.96 on Nov 20, down 4.71% on the day. The next earnings report for VRDN is expected around Thu, Feb 25, 2027. Over its last 8 reports the stock moved an average of 9.7% the session after earnings. Over the last 12 months VRDN insiders bought $20.0M of stock on the open market and sold $419K, according to SEC Form 4 filings.

AI Auto Pilots
Is VRDN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold VRDN.

Key Stats

Last 12 months
Results
Revenue
$26.3M
−62.8% vs a year ago
Net income
−$453.6M
−1724.1% margin
Free cash flow
−$343.4M
−1305.4% margin
Operating margin
−1781.4%
−$468.7M operating income
Valuation
Market cap
$3.4B
113.6M shares
P/E
–
Price to sales
129.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$172.9M
At Sep 30
Debt
$242.5M
At Sep 30
Shareholder equity
$580.7M
Shares outstanding
113.6M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $3.0M$3.0MFY2021FY2022: $1.8M$1.8MFY2022FY2023: $314K$314KFY2023FY2024: $302K$302KFY2024FY2025: $70.8M$70.8MFY2025

From VRDN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · Time not announced
Reported EPS
—
Quarter ended Sep 2026
Year ago EPS
—
Same quarter last year
Revenue
$25.8M
−63.5% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Not enough quarters on file yet.
Revenue by quarter
Dec 2024: $72,000Dec '24Mar 2025: $72,000Mar '25Jun 2025: $75,000Jun '25Sep 2025: $70.6MSep '25Dec 2025: $132,000Dec '25Mar 2026: $141,000Mar '26Jun 2026: $284,000Jun '26Sep 2026: $25.8MSep '26Latest $25.8M
How VRDN moved after its last 8 reports
Average move the session after a report ±9.7%
Nov 4, 2026Time not announced+15.5%
Aug 6, 2026Time not announced+6.8%
May 5, 2026Time not announced+33.4%
Feb 26, 2026Time not announced+1.9%
Oct 21, 2025After the close−8.8%
Aug 6, 2025Time not announced−1.4%
May 6, 2025Time not announced−8.3%
Feb 27, 2025Time not announced−1.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on VRDNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on VRDN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on VRDN

Technical Analysis

VRDN · as of the Nov 20 close · updated each morning
Uptrend, nearing overbought

The stock is 6% above its 20 day and 21% above its 50 day average. It is 28% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 64), near overbought. The nearest support is the Pivot S1 at $29.30, and the nearest resistance the Pivot at $30.53.

Short trendBullish
Long trendBullish
MomentumImproving
StretchNear overbought
VolatilityHigh, 4.6%/day
Key levels
$34.2952 week high+14.5%
$31.63Swing high (Nov 11)+5.6%
$31.18Pivot R1+4.1%
$30.53Pivot+1.9%
$29.96Last close
$29.30Pivot S1−2.2%
$29.25Swing low (Nov 17)−2.4%
$28.1420 day average−6.1%
$23.5350 day average−21.5%
$22.46100 day average−25.0%
$21.52200 day average−28.2%
$13.1852 week low−56.0%
Indicators
RSI (14)64.01Strong, overbought above 70Neutral
MACD2.23Below its signal lineBearish
Stochastic84.3Near the top of its rangeOverbought
ADX (14)53.0Strong uptrend
Williams %R-24.8Oversold below −80, overbought above −20Neutral
CCI (20)65.8Oversold below −100, overbought above 100Neutral
Rate of change+5.2%Change over 10 sessionsBullish
ATR (14)$1.37Typical daily range, 4.6% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for VRDN

What happened before

See how VRDN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow VRDN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How VRDN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for VRDNHow many large options trades hit VRDN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

VRDN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲125 buying vs 86 selling
  • ▲Held by funds +1.1 pts
  • ▲Funds holding +18
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding235217+8.3%
In funds' top 1097+28.6%
Held by funds120.9%119.8%+1.1 pts
New / increased42 / 8346 / 95−11.3%
Reduced / sold out62 / 2449 / 55−17.3%
Put/call ratio79.730.09+85060.2%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VRDN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

VRDN Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$20.0M1 buy · 1 insider
Sold$419K2 sales · 1 insider
2025-12 sold $71K2026-05 bought $20.0M2026-08 sold $348KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 19Jennifer TousignantChief Legal OfficerSale14,212$24.50$348K
May 11Fairmount Funds Management LLCDirectorBuy1,176,470$17.00$20.0M
Dec 31, 2025Jennifer TousignantChief Legal OfficerSale2,272$31.16$71K
Oct 23, 2025Fairmount Healthcare Fund II GP LLCDirectorBuy454,545$22.00$10.0M
Every insider buy and sale for VRDN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See VRDN insider trades →

From SEC Form 4 filings by VRDN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VRDN is in one of them and how their past VRDN trades turned out.

VRDN in the AI portfolios
Loading…

VRDN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VRDN in an article yet. Here's the latest on the wider market.

VRDN in the news

About Viridian Therapeutics

Viridian Therapeutics is a biopharmaceutical company based in Waltham, Massachusetts. It develops medicines for serious and rare diseases, with its main focus on thyroid eye disease, a rare autoimmune condition that affects the eyes. Its pipeline includes antibody treatments that target the IGF-1R pathway and engineered FcRn inhibitors being studied for several autoimmune disorders. The company is preparing to sell its medicines to patients, physicians and insurers if they are approved.

Headquarters
Waltham, MA